Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV.
Adenocarcinoma
/ diagnosis
Adult
Aged
Aged, 80 and over
Cell Line, Tumor
Dipeptidyl Peptidase 4
/ metabolism
Early Detection of Cancer
Esophageal Neoplasms
/ diagnosis
Esophagogastric Junction
/ metabolism
Female
Fluorescent Dyes
/ chemistry
Humans
Male
Middle Aged
Molecular Imaging
Optical Imaging
Prospective Studies
Rhodamines
/ chemistry
Sensitivity and Specificity
Adenocarcinoma of the esophagogastric junction
Dipeptidyl peptidase-IV
Fluorescence imaging
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
28 Jan 2020
28 Jan 2020
Historique:
received:
18
06
2019
accepted:
13
01
2020
entrez:
30
1
2020
pubmed:
30
1
2020
medline:
29
8
2020
Statut:
epublish
Résumé
It is still difficult to detect and diagnose early adenocarcinoma of the esophagogastric junction (EGJ) using conventional endoscopy or image-enhanced endoscopy. A glutamylprolyl hydroxymethyl rhodamine green (EP-HMRG) fluorescent probe that can be enzymatically activated to become fluorescent after the cleavage of a dipeptidyl peptidase (DPP)-IV-specific sequence has been developed and is reported to be useful for the detection of squamous cell carcinoma of the head and neck, and esophagus; however, there is a lack of studies that focuses on detecting EGJ adenocarcinoma by fluorescence molecular imaging. Therefore, we investigated the visualization of early EGJ adenocarcinoma by applying EP-HMRG and using clinical samples resected by endoscopic submucosal dissection (ESD). Fluorescence imaging with EP-HMRG was performed in 21 clinical samples resected by ESD, and the fluorescence intensity of the tumor and non-tumor regions of interest was prospectively measured. Immunohistochemistry was also performed to determine the expression of DPP-IV. Fluorescence imaging of the clinical samples showed that the tumor lesions were visualized within a few minutes after the application of EP-HMRG, with a sensitivity, specificity, and accuracy of 85.7, 85.7, and 85.7%, respectively. However, tumors with a background of intestinal metaplasia did not have a sufficient contrast-to-background ratio since complete intestinal metaplasia also expresses DPP-IV. Immunohistochemistry measurements revealed that all fluorescent tumor lesions expressed DPP-IV. Fluorescence imaging with EP-HMRG could be useful for the detection of early EGJ adenocarcinoma lesions that do not have a background of intestinal metaplasia.
Sections du résumé
BACKGROUND
BACKGROUND
It is still difficult to detect and diagnose early adenocarcinoma of the esophagogastric junction (EGJ) using conventional endoscopy or image-enhanced endoscopy. A glutamylprolyl hydroxymethyl rhodamine green (EP-HMRG) fluorescent probe that can be enzymatically activated to become fluorescent after the cleavage of a dipeptidyl peptidase (DPP)-IV-specific sequence has been developed and is reported to be useful for the detection of squamous cell carcinoma of the head and neck, and esophagus; however, there is a lack of studies that focuses on detecting EGJ adenocarcinoma by fluorescence molecular imaging. Therefore, we investigated the visualization of early EGJ adenocarcinoma by applying EP-HMRG and using clinical samples resected by endoscopic submucosal dissection (ESD).
METHODS
METHODS
Fluorescence imaging with EP-HMRG was performed in 21 clinical samples resected by ESD, and the fluorescence intensity of the tumor and non-tumor regions of interest was prospectively measured. Immunohistochemistry was also performed to determine the expression of DPP-IV.
RESULTS
RESULTS
Fluorescence imaging of the clinical samples showed that the tumor lesions were visualized within a few minutes after the application of EP-HMRG, with a sensitivity, specificity, and accuracy of 85.7, 85.7, and 85.7%, respectively. However, tumors with a background of intestinal metaplasia did not have a sufficient contrast-to-background ratio since complete intestinal metaplasia also expresses DPP-IV. Immunohistochemistry measurements revealed that all fluorescent tumor lesions expressed DPP-IV.
CONCLUSIONS
CONCLUSIONS
Fluorescence imaging with EP-HMRG could be useful for the detection of early EGJ adenocarcinoma lesions that do not have a background of intestinal metaplasia.
Identifiants
pubmed: 31992267
doi: 10.1186/s12885-020-6537-9
pii: 10.1186/s12885-020-6537-9
pmc: PMC6988364
doi:
Substances chimiques
Fluorescent Dyes
0
Rhodamines
0
DPP4 protein, human
EC 3.4.14.5
Dipeptidyl Peptidase 4
EC 3.4.14.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
64Subventions
Organisme : Grant-in-Aid(C)
ID : JSPS, 17K09343
Références
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Dis Esophagus. 2008;21(7):645-9
pubmed: 18459993
Gastric Cancer. 2010 Jun;13(2):63-73
pubmed: 20602191
J Gastroenterol Hepatol. 2008 Dec;23(12):1785-93
pubmed: 19120871
Oncol Rep. 2014 Jun;31(6):2820-6
pubmed: 24789592
N Engl J Med. 1986 Aug 7;315(6):362-71
pubmed: 2874485
Gut. 2014 Jan;63(1):7-42
pubmed: 24165758
Dig Endosc. 2013 May;25 Suppl 2:146-50
pubmed: 23617667
Histol Histopathol. 2004 Oct;19(4):1345-51
pubmed: 15375776
Sci Rep. 2016 Jun 01;6:26399
pubmed: 27245876
Digestion. 2018;97(1):38-44
pubmed: 29393168
J Med Chem. 2014 Mar 27;57(6):2197-212
pubmed: 24099035
Esophagus. 2017;14(1):1-36
pubmed: 28111535
Ann Intern Med. 2003 Feb 4;138(3):176-86
pubmed: 12558356
Int J Oncol. 2004 Nov;25(5):1223-32
pubmed: 15492809
Oncology. 2008;75(1-2):49-59
pubmed: 18787344
Dig Liver Dis. 2015 Jan;47(1):37-44
pubmed: 25454708
J Gastroenterol Hepatol. 2009 May;24(5):729-35
pubmed: 19646015
Gastroenterology. 2011 Mar;140(3):1084-91
pubmed: 21376940
Gastroenterology Res. 2011 Oct;4(5):203-209
pubmed: 27957016
Head Neck. 2018 Jul;40(7):1466-1475
pubmed: 29509281
Int J Cancer. 1995 Oct 20;64(5):326-31
pubmed: 7591305
Gut. 2006 Apr;55(4):442
pubmed: 16531521
Gastric Cancer. 2017 Mar;20(Suppl 1):84-91
pubmed: 27995482
J Androl. 2000 Mar-Apr;21(2):220-6
pubmed: 10714816
Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51
pubmed: 26526079
Gut. 2005 Mar;54 Suppl 1:i27-32
pubmed: 15711005
Dig Endosc. 2013 May;25 Suppl 2:162-7
pubmed: 23617670
Histopathology. 2007 Oct;51(4):515-9
pubmed: 17711448
Br J Surg. 2002 Mar;89(3):344-8
pubmed: 11872061